These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11777318)

  • 1. The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
    Huang JY; Wu MS; Wu CH
    Ren Fail; 2001 Nov; 23(6):789-95. PubMed ID: 11777318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of body iron stores on serum aluminum level in hemodialysis patients.
    Huang JY; Huang CC; Lim PS; Wu MS; Leu ML
    Nephron; 1992; 61(2):158-62. PubMed ID: 1630539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
    Tarng DC; Huang TP
    Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant iron and aluminum mass transfer following deferoxamine infusion during hemofiltration.
    Canavese C; Salomone M; Pacitti A; Mangiarotti G; Thea A; Dogliani M; Serra A
    Am J Kidney Dis; 1991 Feb; 17(2):179-84. PubMed ID: 1992660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
    Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
    Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
    Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
    Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
    Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
    Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
    Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
    Andriani M; Nordio M; Saporiti E
    Nephron; 1996; 72(2):218-24. PubMed ID: 8684530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
    Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
    Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
    Takasawa K; Takaeda C; Wada T; Ueda N
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.